Allianthera (Suzhou) Biopharmaceutical Co. Ltd. has patented new aryl hydrocarbon receptor (AhR) agonists reported to be useful for the treatment of cancer, lung diseases, bone, dermatological, eye, gastrointestinal, neurological and pancreatic disorders, among others.